EA201991492A1 - Антитела к lif и их применения - Google Patents

Антитела к lif и их применения

Info

Publication number
EA201991492A1
EA201991492A1 EA201991492A EA201991492A EA201991492A1 EA 201991492 A1 EA201991492 A1 EA 201991492A1 EA 201991492 A EA201991492 A EA 201991492A EA 201991492 A EA201991492 A EA 201991492A EA 201991492 A1 EA201991492 A1 EA 201991492A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
lif
application
cancer
treatment
Prior art date
Application number
EA201991492A
Other languages
English (en)
Inventor
Джон Сеоане Суарез
Джудит Анидо Фолгуэйра
Йохан Франссон
Жан-Филиппе Жулиен
Швета Раман
Original Assignee
Мозаик Биомедикалс, С.Л.Ю.
Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс
Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мозаик Биомедикалс, С.Л.Ю., Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс, Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн filed Critical Мозаик Биомедикалс, С.Л.Ю.
Priority claimed from PCT/IB2017/001677 external-priority patent/WO2018115960A1/en
Publication of EA201991492A1 publication Critical patent/EA201991492A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

В настоящем документе описаны антитела, нацеленные на лейкоз-ингибирующий фактор (LIF). Также в настоящем документе описаны применения таких антител для лечения рака.
EA201991492A 2017-10-13 2017-12-18 Антитела к lif и их применения EA201991492A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382683 2017-10-13
PCT/IB2017/001677 WO2018115960A1 (en) 2016-12-19 2017-12-18 Antibodies against lif and uses thereof

Publications (1)

Publication Number Publication Date
EA201991492A1 true EA201991492A1 (ru) 2020-04-23

Family

ID=60201972

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991492A EA201991492A1 (ru) 2017-10-13 2017-12-18 Антитела к lif и их применения

Country Status (2)

Country Link
EA (1) EA201991492A1 (ru)
PT (1) PT3555132T (ru)

Also Published As

Publication number Publication date
PT3555132T (pt) 2024-01-24

Similar Documents

Publication Publication Date Title
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
MD3582853T2 (ro) Compuși di-nucleotidici ciclici pentru tratamentul cancerului
CY1123977T1 (el) Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EA201990615A1 (ru) Пирролобензодиазепиновые конъюгаты
TR201901445T4 (tr) Il2rbeta/yaygın gamma zinciri antikorları.
EA202092435A2 (ru) Моноклональные антитела против bcma
EA201790413A1 (ru) Антитела против tigit
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201791046A8 (ru) Макроциклические пептиды, используемые в качестве иммуномодуляторов
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201991997A1 (ru) Комбинированная терапия
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
EA201800148A1 (ru) Оспенная вакцина для лечения рака
MX2020007748A (es) Metodos para tratar canceres con anticuerpos anti-pd-1 antagonistas.
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
EA201791391A1 (ru) Способы получения соединения диарилтиогидантоин
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
MX2019007376A (es) Anticuerpos contra el lif y usos de los mismos.